Patents by Inventor Michael Angelastro

Michael Angelastro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • UDP glycosyltransferase inhibitors and methods of use
    Patent number: 11098056
    Abstract: Described herein is a compound of Formula (I), and pharmaceutically acceptable salts thereof. Also described herein are compositions and the use of such compositions in methods of treating a variety of diseases and conditions, in particular Krabbe's Disease (KD) and Metachromatic leukodystrophy (MLD).
    Type: Grant
    Filed: October 1, 2019
    Date of Patent: August 24, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Sungtaek Lim, Robert H. Barker, Jr., Mary A. Cromwell, Elina Makino, Bradford Hirth, John Jiang, Sachin Maniar, Mark Munson, Yong-Mi Choi, Sukanthini Thurairatnam, Kwon Yon Musick, James Pribish, Michael Angelastro
  • UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE
    Publication number: 20200102324
    Abstract: Described herein is a compound of Formula (I), and pharmaceutically acceptable salts thereof. Also described herein are compositions and the use of such compositions in methods of treating a variety of diseases and conditions, in particular Krabbe's Disease (KD) and Metachromatic leukodystrophy (MLD).
    Type: Application
    Filed: October 1, 2019
    Publication date: April 2, 2020
    Inventors: Sungtaek LIM, Robert H. BARKER, JR., Mary A. CROMWELL, Elina MAKINO, Bradford HIRTH, John JIANG, Sachin MANIAR, Mark MUNSON, Yong-Mi CHOI, Sukanthini THURAIRATNAM, Kwon Yon MUSICK, James PRIBISH, Michael ANGELASTRO
  • Method for Determining the Stability of Organic Methyleneamines in the Presence of Semicarbazide-Sensitive Amine Oxidase
    Publication number: 20140363836
    Abstract: The present invention provides methods for determining the stability of methyleneamine, methyleneamine-like compounds or compounds containing an methyleneamine moiety in the presence of semicarbazide-sensitive amine oxidase (SSAO) or a biological sample containing SSAO activity. The disclosed methods may be configured in an assay format for high throughput screening applications.
    Type: Application
    Filed: May 12, 2014
    Publication date: December 11, 2014
    Inventors: Adedayo ADEDOYIN, Michael ANGELASTRO, Julie BICK, Jennifer CAIRNS, Yongqing HUANG, Guyan LIANG, Heng-Keang LIM
  • METHOD FOR DETERMINING THE STABILITY OF ORGANIC METHYLENEAMINES IN THE PRESENCE OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE
    Publication number: 20100028895
    Abstract: The present invention provides methods for determining the stability of methyleneamine, methyleneamine-like compounds or compounds containing an methyleneamine moiety in the presence of semicarbazide-sensitive amine oxidase (SSAO) or a biological sample containing SSAO activity. The disclosed methods may be configured in an assay format for high throughput screening applications.
    Type: Application
    Filed: January 8, 2008
    Publication date: February 4, 2010
    Inventors: Adedayo Adedoyin, Michael Angelastro, Julie Bick, Jennifer Cairns, Yongqing Huang, Guyan Liang, Heng-Keang Lim
  • Furosemide modulators of HM74
    Patent number: 7556931
    Abstract: Host cells expressing HM74 were used to obtain furosemide-like molecules with agonist activity having the following structure formula:
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: July 7, 2009
    Assignees: Aventis Pharmaceuticals Inc., sanof-aventis Deutschland GmbH
    Inventors: Ann Minnich, Theresa Kuntzweiler, Haifeng Eishingdrelo, Michael Angelastro, Hans-Jochen Lang
  • OXYDECAHYDRONAPHTHALENE MODULATORS OF HM74
    Publication number: 20080045586
    Abstract: Host cells expressing HM74 were used to obtain oxydecalin-like molecules with agonist activity having the following structure:
    Type: Application
    Filed: August 30, 2007
    Publication date: February 21, 2008
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Anne MINNICH, Theresa KUNTZWEILER, Haifeng EISHINGDRELO, Michael ANGELASTRO, Stephan HENKE
  • FUROSEMIDE MODULATORS OF HM74
    Publication number: 20070213391
    Abstract: Host cells expressing HM74 were used to obtain furosemide-like molecules with agonist activity having the following structure formula:
    Type: Application
    Filed: May 7, 2007
    Publication date: September 13, 2007
    Applicants: AVENTIS PHARMACEUTICALS INC., AVENTIS PHARMA DEUTSCHLAND GMBH
    Inventors: Ann MINNICH, Theresa KUNTZWEILER, Haifeng EISHINGDRELO, Michael ANGELASTRO, Hans-Jochen LANG
  • Oxydecahydronaphthalene modulators of HM74
    Patent number: 7264937
    Abstract: Host cells expressing HM74 were used to obtain oxydecalin-like molecules with agonist activity having the following structure:
    Type: Grant
    Filed: February 14, 2005
    Date of Patent: September 4, 2007
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Anne Minnich, Theresa Kuntzweiler, Haifeng Eishingdrelo, Michael Angelastro, Stephan Henke
  • Furosemide modulators of HM74
    Patent number: 7232811
    Abstract: Host cells expressing HM74 were used to obtain furosemide-like molecules with agonist activity having the following structure formula:
    Type: Grant
    Filed: February 14, 2005
    Date of Patent: June 19, 2007
    Assignees: Aventis Pharmaceuticals Inc., Sanofi-Aventis Deutschland GmbH
    Inventors: Anne Minnich, Theresa Kuntzweiler, Haifeng Eishingdrelo, Michael Angelastro, Hans-Jochen Lang
  • 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS
    Publication number: 20070099955
    Abstract: The present invention provides compounds of formula I: a stereoisomer or a pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R3, R4, X and n are defined as defined herein. Additionally, a method for treating dopamine-related neurological disorders selected form the group consisting of neurological, psychological, cardiovascular, cognitive or attention disorders, substance abuse and addictive behavior, or a combination thereof, comprising administering to a patient in need of such treatment a therapeutically effective amount of compounds of formula I.
    Type: Application
    Filed: October 24, 2006
    Publication date: May 3, 2007
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Gregory Shutske, Keith Harris, Kenneth Bordeau, Michael Angelastro, Stanly John, Joseph Klein, Jinqi Lu, Catherine Bomont
  • Oxydecahydronaphthalene modulators of HM74
    Publication number: 20050187263
    Abstract: Host cells expressing HM74 were used to obtain oxydecalin-like molecules with agonist activity having the following structure:
    Type: Application
    Filed: February 14, 2005
    Publication date: August 25, 2005
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Anne Minnich, Theresa Kuntzweiler, Haifeng Eishingdrelo, Michael Angelastro, Stephan Henke
  • Furosemide modulators of HM74
    Publication number: 20050187280
    Abstract: Host cells expressing HM74 were used to obtain furosemide-like molecules with agonist activity having the following structure formula:
    Type: Application
    Filed: February 14, 2005
    Publication date: August 25, 2005
    Applicants: Aventis Pharmaceuticals Inc., Aventis Pharma Deutschland GmbH
    Inventors: Anne Minnich, Theresa Kuntzweiler, Haifeng Eishingdrelo, Michael Angelastro, Hans-Jochen Lang